HC Wainwright reiterated their buy rating on shares of Exicure (NYSE:XCUR) in a report released on Wednesday morning, Zacks.com reports.
NYSE XCUR traded down $0.13 on Wednesday, hitting $2.49. 32,968 shares of the company’s stock traded hands, compared to its average volume of 67,962. Exicure has a 1-year low of $1.62 and a 1-year high of $4.20.
Exicure (NYSE:XCUR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.53 million for the quarter.
Exicure, Inc, a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis.
Further Reading: Intrinsic Value
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.